Dr. Adedayo A. Onitilo, MD

Dr. Onitilo practices at Marshfield Medical Center - Marshfield in Marshfield, Wisconsin, part of Sanford Health.

Dr. Onitilo's NPI, 1275631566, was assigned on September 20, 2006. Dr. Onitilo holds Wisconsin license 46194.

Dr. Onitilo's primary practice is Marshfield Medical Center - Marshfield, at 611 St Joseph Ave, Marshfield, WI 54449 in Wood County. The practice phone is (715) 387-9963.

Dr. Onitilo's primary practice is Marshfield Medical Center - Marshfield in Marshfield, Wisconsin, part of Sanford Health. Dr. Onitilo is also affiliated with Aspirus Stevens Point Hospital. The medical group on file is Marshfield Clinic Health System. Dmand AI also links Dr. Onitilo to 3 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account. Dr. Onitilo's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Onitilo practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Onitilo's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Onitilo is licensed in Wisconsin.

CMS data shows 1,880 Medicare services from Dr. Onitilo across 6 procedure codes in 2024, for 568 Medicare patients. Medicare paid $115,770 for them.

CMS counts 568 Medicare patients who saw Dr. Onitilo in 2024. The largest group is 65 to 74, with 274 patients. 70% of them have high blood pressure, and 66% have high cholesterol. 14% are also on Medicaid. Their average risk score is 1.61, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Onitilo's median patient age at 73, with 58% women.

In 2024, Dr. Onitilo wrote 332 Medicare Part D claims for 87 patients. 83% of them were for generic drugs. CMS names the drug for 224 of them, across 9 drugs with 11 or more claims each, at $346,028 in total drug cost. In 2023, CMS named 547 claims across 17 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Onitilo for performance year 2024, reported as part of a group. Dr. Onitilo accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Onitilo as offering telehealth.

Dmand AI links 104 papers to Dr. Onitilo, published from 2011 to 2025. 2021 was the busiest year, with 12. The most frequent topics are Breast Neoplasms, Antineoplastic Agents and Mammography. Dr. Onitilo has published most often in Clin Med Res. Dr. Onitilo's most frequent co-authors are Supriya Gupta Mohile, MD, Sabo Bukar Tanimu, MD and Onyinye Balogun, MD.

Dmand AI links Dr. Onitilo to 10 clinical trials, 4 of them phase 3 studies. 9 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Adenocarcinoma of Lung. National Cancer Institute (NCI) sponsors the most, 7.

CMS Open Payments shows 146 general payments to Dr. Onitilo from 25 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 73% of the total. Incyte Corporation paid the most, $17,083. It also lists 1 research payment totaling $28,457 in 2022.